Načítá se...
A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3...
Uloženo v:
Hlavní autoři: | , , , , , , , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
The Korean Academy of Medical Sciences
2005
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2782154/ https://ncbi.nlm.nih.gov/pubmed/16100450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2005.20.4.598 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|